Pharmaceutical company Bluefish Pharmaceuticals AB has acquired BMM Pharma AB, a subsidiary of BioPhausia AB.
The portfolio acquired includes 19 pharmaceutical products, of which most are used in pain, inflammation and gastrointestinal therapy. Following the acquisition, Bluefish now has 68 products in its portfolio, of which 41 have already been launched.
The acquisition is expected to increase net sales by approximately SEK 30 million. No personnel are included in the acquisition. The acquisition will be financed by means of a bridging loan from Färna Invest AB, which has also entered into an agreement for a new share issue.
Bluefish Pharmaceuticals was founded in 2005 and focuses on the development, manufacture and sale of generic pharmaceuticals.
Wistrand advised Bluefish in the acquisition, primarily through partners Lars hasp and Magnus Forssman.
For further information:
Magnus Forssman, partner Wistrand
Direct: +46 8 50 72 0069
Mobile: +46 709 50 72 69